Antiviral Drugs Market Size By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), By Age Group (Pediatric, Adult, Geriatric), Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Mar 2021  |  Report ID: GMI4968  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 200   |   Base Year: 2020




Report Content

Chapter 1   Methodology

1.1    Market definitions

1.2    Base estimates and working

1.2.1    North America

1.2.2    Europe

1.2.3    Asia Pacific

1.2.4    Latin America

1.2.5    MEA

1.3    Forecast calculations

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Anti-viral drugs market industry 3600 synopsis

2.1.1    Business trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

2.1.6    Regional trends

Chapter 3   Anti-viral Drugs Market Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027 (USD Million)

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Increasing prevalence of viral infections including COVID-19

3.3.1.2    Presence of pipeline products for HIV treatment

3.3.1.3    Increasing geriatric population

3.3.2    Industry pitfalls & challenges

3.3.2.1    Presence of generics

3.3.2.2    Rising awareness about preventive drugs treatment

3.3.2.3    Drug resistance

3.4    Growth potential analysis

3.4.1    By drug class

3.4.2    By indication

3.4.3    By drug class

3.4.4    By age group

3.5    COVID-19 impact analysis

3.6    Regulatory landscape

3.7    Reimbursement scenario

3.8    Porter's analysis

3.9    Competitive landscape, 2020

3.10    PESTEL analysis

Chapter 4   Anti-viral Drugs Market, By Drug Class

4.1    Key segment trends

4.2    DNA polymerase inhibitors

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Reverse transcript inhibitors

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.4    Protease inhibitors

4.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.5    Neuraminidase Inhibitors

4.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.6    Others

4.6.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 5   Anti-viral Drugs Market, By Indication

5.1    Key segment trends

5.2    Influenza

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    HIV AIDS

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Hepatitis

5.4.1    Market size, by region, 2016 – 2027 (USD Million)

5.5    Herpes simplex virus (HSV)

5.5.1    Market size, by region, 2016 – 2027 (USD Million)

5.6    Coronavirus infection

5.6.1    Market size, by region, 2016 – 2027 (USD Million)

5.7    Others

5.7.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 6   Anti-viral Drugs Market, By Type

6.1    Key segment trends

6.2    Branded

6.2.1    Market size, by region, 2016 – 2027 (USD Million)

6.3    Generic

6.3.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 7   Anti-viral Drugs Market, By Age Group

7.1    Key segment trends

7.2    Adult

7.2.1    Market size, by region, 2016 – 2027 (USD Million)

7.3    Pediatric

7.3.1    Market size, by region, 2016 – 2027 (USD Million)

7.4    Geriatric

7.4.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 8   Anti-viral Drugs Market, By Region

8.1    Key regional trends

8.2    North America

8.2.1    Market size, by country, 2016 – 2027 (USD Million)

8.2.2    Market size, by drug class, 2016 – 2027 (USD Million)

8.2.3    Market size, by indication, 2016-2027 (USD Million)

8.2.4    Market size, by type, 2016-2027 (USD Million)

8.2.5    Market size, by age group, 2016 – 2027 (USD Million)

8.2.6    U.S.

8.2.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.2.6.2    Market size, by indication, 2016 – 2027 (USD Million)

8.2.6.3    Market size, by type, 2016 – 2027 (USD Million)

8.2.6.4    Market size, by age group, 2016 – 2027 (USD Million)

8.2.7    Canada

8.2.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.2.7.2    Market size, by indication, 2016 – 2027 (USD Million)

8.2.7.3    Market size, by type, 2016 – 2027 (USD Million)

8.2.7.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3    Europe

8.3.1    Market size, by country, 2016 – 2027 (USD Million)

8.3.2    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.3    Market size, by indication, 2016-2027 (USD Million)

8.3.4    Market size, by type, 2016-2027 (USD Million)

8.3.5    Market size, by age group, 2016 – 2027 (USD Million)

8.3.6    Germany

8.3.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.6.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.6.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.6.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.7    UK

8.3.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.7.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.7.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.7.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.8    France

8.3.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.8.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.8.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.8.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.9    Spain

8.3.9.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.9.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.9.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.9.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.10    Italy

8.3.10.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.10.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.10.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.10.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.11    Russia

8.3.11.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.11.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.11.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.11.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.12    Poland

8.3.12.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.12.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.12.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.12.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.13    Switzerland

8.3.13.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.13.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.13.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.13.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.14    Netherlands

8.3.14.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.14.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.14.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.14.4    Market size, by age group, 2016 – 2027 (USD Million)

8.3.15    Sweden

8.3.15.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.3.15.2    Market size, by indication, 2016 – 2027 (USD Million)

8.3.15.3    Market size, by type, 2016 – 2027 (USD Million)

8.3.15.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4    Asia Pacific

8.4.1    Market size, by country, 2016 – 2027 (USD Million)

8.4.2    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.3    Market size, by indication, 2016-2027 (USD Million)

8.4.4    Market size, by type, 2016-2027 (USD Million)

8.4.5    Market size, by age group, 2016 – 2027 (USD Million)

8.4.6    Japan

8.4.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.6.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.6.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.6.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.7    China

8.4.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.7.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.7.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.7.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.8    India

8.4.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.8.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.8.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.8.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.9    Australia

8.4.9.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.9.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.9.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.9.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.10    South Korea

8.4.10.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.10.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.10.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.10.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.11    Singapore

8.4.11.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.11.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.11.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.11.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.12    Indonesia

8.4.12.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.12.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.12.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.12.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.13    Thailand

8.4.13.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.13.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.13.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.13.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.14    Malaysia

8.4.14.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.14.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.14.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.14.4    Market size, by age group, 2016 – 2027 (USD Million)

8.4.15    Philippines

8.4.15.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.4.15.2    Market size, by indication, 2016 – 2027 (USD Million)

8.4.15.3    Market size, by type, 2016 – 2027 (USD Million)

8.4.15.4    Market size, by age group, 2016 – 2027 (USD Million)

8.5    Latin America

8.5.1    Market size, by country, 2016 – 2027 (USD Million)

8.5.2    Market size, by drug class, 2016 – 2027 (USD Million)

8.5.3    Market size, by indication, 2016-2027 (USD Million)

8.5.4    Market size, by type, 2016-2027 (USD Million)

8.5.5    Market size, by age group, 2016 – 2027 (USD Million)

8.5.6    Brazil

8.5.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.5.6.2    Market size, by indication, 2016 – 2027 (USD Million)

8.5.6.3    Market size, by type, 2016 – 2027 (USD Million)

8.5.6.4    Market size, by age group, 2016 – 2027 (USD Million)

8.5.7    Mexico

8.5.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.5.7.2    Market size, by indication, 2016 – 2027 (USD Million)

8.5.7.3    Market size, by type, 2016 – 2027 (USD Million)

8.5.7.4    Market size, by age group, 2016 – 2027 (USD Million)

8.5.8    Argentina

8.5.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.5.8.2    Market size, by indication, 2016 – 2027 (USD Million)

8.5.8.3    Market size, by type, 2016 – 2027 (USD Million)

8.5.8.4    Market size, by age group, 2016 – 2027 (USD Million)

8.6    Middle East & Africa

8.6.1    Market size, by country, 2016 – 2027 (USD Million)

8.6.2    Market size, by drug class, 2016 – 2027 (USD Million)

8.6.3    Market size, by indication, 2016-2027 (USD Million)

8.6.4    Market size, by type, 2016-2027 (USD Million)

8.6.5    Market size, by age group, 2016 – 2027 (USD Million)

8.6.6    Saudi Arabia

8.6.6.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.6.6.2    Market size, by indication, 2016 – 2027 (USD Million)

8.6.6.3    Market size, by type, 2016 – 2027 (USD Million)

8.6.6.4    Market size, by age group, 2016 – 2027 (USD Million)

8.6.7    South Africa

8.6.7.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.6.7.2    Market size, by indication, 2016 – 2027 (USD Million)

8.6.7.3    Market size, by type, 2016 – 2027 (USD Million)

8.6.7.4    Market size, by age group, 2016 – 2027 (USD Million)

8.6.8    UAE

8.6.8.1    Market size, by drug class, 2016 – 2027 (USD Million)

8.6.8.2    Market size, by indication, 2016 – 2027 (USD Million)

8.6.8.3    Market size, by type, 2016 – 2027 (USD Million)

8.6.8.4    Market size, by age group, 2016 – 2027 (USD Million)

Chapter 9   Company Profiles

9.1    Competitive dashboard, 2020

9.2    Gilead Sciences, Inc

9.2.1    Business overview

9.2.2    Financial data

9.2.3    Product landscape

9.2.4    Strategic outlook

9.2.5    SWOT analysis

9.3    Johnson & Johnson

9.3.1    Business overview

9.3.2    Financial data

9.3.3    Product landscape

9.3.4    Strategic outlook

9.3.5    SWOT analysis

9.4    GlaxoSmithKline

9.4.1    Business overview

9.4.2    Financial data

9.4.3    Product landscape

9.4.4    Strategic outlook

9.4.5    SWOT analysis

9.5    AbbVie, Inc

9.5.1    Business overview

9.5.2    Financial data

9.5.3    Product landscape

9.5.4    Strategic outlook

9.5.5    SWOT analysis

9.6.     Merck & Co.,

9.6.1    Business overview

9.6.2    Financial data

9.6.3    Product landscape

9.6.4    Strategic outlook

9.6.5    SWOT analysis

9.7    Bristol Myers Squibb

9.7.1    Business overview

9.7.2    Financial data

9.7.3    Product landscape

9.7.4    Strategic outlook

9.7.5    SWOT analysis

9.8    Aurobindo Pharma Limited

9.8.1    Business overview

9.8.2    Financial data

9.8.3    Product landscape

9.8.4    Strategic outlook

9.8.5    SWOT analysis

9.9    Sun Pharmaceutical Industries Ltd

9.9.1    Business overview

9.9.2    Financial data

9.9.3    Product landscape

9.9.4    Strategic outlook

9.9.5    SWOT analysis

9.10    Cipla, Inc.

9.10.1    Business overview

9.10.2    Financial data

9.10.3    Product landscape

9.10.4    Strategic outlook

9.10.5    SWOT analysis

9.11    Mylan N V

9.11.1    Business overview

9.11.2    Financial data

9.11.3    Product landscape

9.11.4    Strategic outlook

9.11.5    SWOT analysis

 

Data Tables

TABLE 1   Anti-viral drugs market, 2016-2027(USD Million)

TABLE 2   Anti-viral drugs market, by drug class, 2016-2027(USD Million)

TABLE 3   Anti-viral drugs market, by indication, 2016-2027(USD Million)

TABLE 4   Anti-viral drugs market, by type, 2016-2027(USD Million)

TABLE 5   Anti-viral drugs market, by age group, 2016-2027(USD Million)

TABLE 6   Anti-viral drugs market, by region, 2016-2027(USD Million)

TABLE 7   Industry impact forces

TABLE 8   DNA polymerase inhibitors market size, by region, 2016-2027(USD Million)

TABLE 9    Reverse transcriptase inhibitors market size, by region, 2016-2027(USD Million)

TABLE 10  Protease inhibitors market size, by region, 2016-2027(USD Million)

TABLE 11  Neuraminidase inhibitors market size, by region, 2016-2027(USD Million)

TABLE 12  Others market size, by region, 2016-2027(USD Million)

TABLE 13  Influenza market size, by region, 2016-2027(USD Million)

TABLE 14  HIV AIDS market size, by region, 2016-2027(USD Million)

TABLE 15  Hepatitis market size, by region, 2016-2027(USD Million)

TABLE 16  Herpes simplex virus market size, by region, 2016-2027(USD Million)

TABLE 17  Coronavirus infection market size, by region, 2016-2027(USD Million)

TABLE 18  Others market size, by region, 2016-2027(USD Million)

TABLE 19  Branded market size, by region, 2016-2027(USD Million)

TABLE 20  Generic market size, by region, 2016-2027(USD Million)

TABLE 21  Adult market size, by region, 2016-2027(USD Million)

TABLE 22  Pediatric market size, by region, 2016-2027(USD Million)

TABLE 23  Geriatric market size, by region, 2016-2027(USD Million)

TABLE 24  North America market size, by country, 2016 – 2027 (USD Million)

TABLE 25  North America market size, by drug class, 2016 – 2027 (USD Million)

TABLE 26  North America market size, by indication, 2016 – 2027 (USD Million)

TABLE 27  North America market size, by type, 2016 – 2027 (USD Million)

TABLE 28  North America market size, by age group, 2016 - 2027 (USD Million)

TABLE 29  U.S. market size, by drug class, 2016 - 2027 (USD Million)

TABLE 30  U.S. market size, by indication, 2016 - 2027 (USD Million)

TABLE 31  U.S. market size, by type, 2016 - 2027 (USD Million)

TABLE 32  U.S. market size, by age group, 2016 - 2027 (USD Million)

TABLE 33  Canada market size, by drug class, 2016 - 2027 (USD Million)

TABLE 34  Canada market size, by indication, 2016 - 2027 (USD Million)

TABLE 35  Canada market size, by type, 2016 - 2027 (USD Million)

TABLE 36  Canada market size, by age group, 2016 - 2027 (USD Million)

TABLE 37  Europe market size, by country, 2016 – 2027 (USD Million)

TABLE 38  Europe market size, by drug class, 2016 – 2027 (USD Million)

TABLE 39  Europe market size, by indication, 2016 – 2027 (USD Million)

TABLE 40  Europe market size, by type, 2016 – 2027 (USD Million)

TABLE 41  Europe market size, by age group, 2016 - 2027 (USD Million)

TABLE 42  Germany market size, by drug class, 2016 - 2027 (USD Million)

TABLE 43  Germany market size, by indication, 2016 - 2027 (USD Million)

TABLE 44  Germany market size, by type, 2016 - 2027 (USD Million)

TABLE 45  Germany market size, by age group, 2016 - 2027 (USD Million)

TABLE 46  UK market size, by drug class, 2016 - 2027 (USD Million)

TABLE 47  UK market size, by indication, 2016 - 2027 (USD Million)

TABLE 48  UK market size, by type, 2016 - 2027 (USD Million)

TABLE 49  UK market size, by age group, 2016 - 2027 (USD Million)

TABLE 50  France market size, by drug class, 2016 - 2027 (USD Million)

TABLE 51  France market size, by indication, 2016 - 2027 (USD Million)

TABLE 52  France market size, by type, 2016 - 2027 (USD Million)

TABLE 53  France market size, by age group, 2016 - 2027 (USD Million)

TABLE 54  Italy market size, by drug class, 2016 - 2027 (USD Million)

TABLE 55  Italy market size, by indication, 2016 - 2027 (USD Million)

TABLE 56  Italy market size, by type, 2016 - 2027 (USD Million)

TABLE 57  Italy market size, by age group, 2016 - 2027 (USD Million)

TABLE 58  Spain market size, by drug class, 2016 - 2027 (USD Million)

TABLE 59  Spain market size, by indication, 2016 - 2027 (USD Million)

TABLE 60  Spain market size, by type, 2016 - 2027 (USD Million)

TABLE 61  Spain market size, by age group, 2016 - 2027 (USD Million)

TABLE 62  Russia market size, by drug class, 2016 - 2027 (USD Million)

TABLE 63  Russia market size, by indication, 2016 - 2027 (USD Million)

TABLE 64  Russia market size, by type, 2016 - 2027 (USD Million)

TABLE 65  Russia market size, by age group, 2016 - 2027 (USD Million)

TABLE 66  Poland market size, by drug class, 2016 - 2027 (USD Million)

TABLE 67  Poland market size, by indication, 2016 - 2027 (USD Million)

TABLE 68  Poland market size, by type, 2016 - 2027 (USD Million)

TABLE 69  Poland market size, by age group, 2016 - 2027 (USD Million)

TABLE 70  Switzerland market size, by drug class, 2016 - 2027 (USD Million)

TABLE 71  Switzerland market size, by indication, 2016 - 2027 (USD Million)

TABLE 72  Switzerland market size, by type, 2016 - 2027 (USD Million)

TABLE 73  Switzerland market size, by age group, 2016 - 2027 (USD Million)

TABLE 74  Netherlands market size, by drug class, 2016 - 2027 (USD Million)

TABLE 75  Netherlands market size, by indication, 2016 - 2027 (USD Million)

TABLE 76  Netherlands market size, by type, 2016 - 2027 (USD Million)

TABLE 77  Netherlands market size, by age group, 2016 - 2027 (USD Million)

TABLE 78  Sweden market size, by drug class, 2016 - 2027 (USD Million)

TABLE 79  Sweden market size, by indication, 2016 - 2027 (USD Million)

TABLE 80  Sweden market size, by type, 2016 - 2027 (USD Million)

TABLE 81  Sweden market size, by age group, 2016 - 2027 (USD Million)

TABLE 82  Asia Pacific market size, by country, 2016 – 2027 (USD Million)

TABLE 83  Asia Pacific market size, by drug class, 2016 – 2027 (USD Million)

TABLE 84  Asia Pacific market size, by indication, 2016 – 2027 (USD Million)

TABLE 85  Asia Pacific market size, by type, 2016 – 2027 (USD Million)

TABLE 86  Asia Pacific market size, by age group, 2016 - 2027 (USD Million)

TABLE 87  Japan market size, by drug class, 2016 - 2027 (USD Million)

TABLE 88  Japan market size, by indication, 2016 - 2027 (USD Million)

TABLE 89  Japan market size, by type, 2016 - 2027 (USD Million)

TABLE 90  Japan market size, by age group, 2016 - 2027 (USD Million)

TABLE 91  China market size, by drug class, 2016 - 2027 (USD Million)

TABLE 92  China market size, by indication, 2016 - 2027 (USD Million)

TABLE 93  China market size, by type, 2016 - 2027 (USD Million)

TABLE 94  China market size, by age group, 2016 - 2027 (USD Million)

TABLE 95  India market size, by drug class, 2016 - 2027 (USD Million)

TABLE 96  India market size, by indication, 2016 - 2027 (USD Million)

TABLE 97  India market size, by type, 2016 - 2027 (USD Million)

TABLE 98  India market size, by age group, 2016 - 2027 (USD Million)

TABLE 99  Australia market size, by drug class, 2016 - 2027 (USD Million)

TABLE 100 Australia market size, by indication, 2016 - 2027 (USD Million)

TABLE 101 Australia market size, by type, 2016 - 2027 (USD Million)

TABLE 102 Australia market size, by age group, 2016 - 2027 (USD Million)

TABLE 103 South Korea market size, by drug class, 2016 - 2027 (USD Million)

TABLE 104 South Korea market size, by indication, 2016 - 2027 (USD Million)

TABLE 105 South Korea market size, by type, 2016 - 2027 (USD Million)

TABLE 106 South Korea market size, by age group, 2016 - 2027 (USD Million)

TABLE 107 Singapore market size, by drug class, 2016 - 2027 (USD Million)

TABLE 108 Singapore market size, by indication, 2016 - 2027 (USD Million)

TABLE 109 Singapore market size, by type, 2016 - 2027 (USD Million)

TABLE 110 Singapore market size, by age group, 2016 - 2027 (USD Million)

TABLE 111 Indonesia market size, by drug class, 2016 - 2027 (USD Million)

TABLE 112 Indonesia market size, by indication, 2016 - 2027 (USD Million)

TABLE 113 Indonesia market size, by type, 2016 - 2027 (USD Million)

TABLE 114 Indonesia market size, by age group, 2016 - 2027 (USD Million)

TABLE 115 Thailand market size, by drug class, 2016 - 2027 (USD Million)

TABLE 116 Thailand market size, by indication, 2016 - 2027 (USD Million)

TABLE 117 Thailand market size, by type, 2016 - 2027 (USD Million)

TABLE 118 Thailand market size, by age group, 2016 - 2027 (USD Million)

TABLE 119 Malaysia market size, by drug class, 2016 - 2027 (USD Million)

TABLE 120 Malaysia market size, by indication, 2016 - 2027 (USD Million)

TABLE 121 Malaysia market size, by type, 2016 - 2027 (USD Million)

TABLE 122 Malaysia market size, by age group, 2016 - 2027 (USD Million)

TABLE 123 Philippines market size, by drug class, 2016 - 2027 (USD Million)

TABLE 124 Philippines market size, by indication, 2016 - 2027 (USD Million)

TABLE 125 Philippines market size, by type, 2016 - 2027 (USD Million)

TABLE 126 Philippines market size, by age group, 2016 - 2027 (USD Million)

TABLE 127 Latin America market size, by country, 2016 – 2027 (USD Million)

TABLE 128 Latin America market size, by drug class, 2016 – 2027 (USD Million)

TABLE 129 Latin America market size, by indication, 2016 – 2027 (USD Million)

TABLE 130 Latin America market size, by type, 2016 – 2027 (USD Million)

TABLE 131 Latin America market size, by age group, 2016 - 2027 (USD Million)

TABLE 132 Brazil market size, by drug class, 2016 - 2027 (USD Million)

TABLE 133 Brazil market size, by indication, 2016 - 2027 (USD Million)

TABLE 134 Brazil market size, by type, 2016 - 2027 (USD Million)

TABLE 135 Brazil market size, by age group, 2016 - 2027 (USD Million)

TABLE 136 Mexico market size, by drug class, 2016 - 2027 (USD Million)

TABLE 137 Mexico market size, by indication, 2016 - 2027 (USD Million)

TABLE 138 Mexico market size, by type, 2016 - 2027 (USD Million)

TABLE 139 Mexico market size, by age group, 2016 - 2027 (USD Million)

TABLE 140 Argentina market size, by drug class, 2016 - 2027 (USD Million)

TABLE 141 Argentina market size, by indication, 2016 - 2027 (USD Million)

TABLE 142 Argentina market size, by type, 2016 - 2027 (USD Million)

TABLE 143 Argentina market size, by age group, 2016 - 2027 (USD Million)

TABLE 144 MEA market size, by country, 2016 – 2027 (USD Million)

TABLE 145 MEA market size, by drug class, 2016 – 2027 (USD Million)

TABLE 146 MEA market size, by indication, 2016 – 2027 (USD Million)

TABLE 147 MEA market size, by type, 2016 – 2027 (USD Million)

TABLE 148 MEA market size, by age group, 2016 - 2027 (USD Million)

TABLE 149 South Africa market size, by drug class, 2016 - 2027 (USD Million)

TABLE 150 South Africa market size, by indication, 2016 - 2027 (USD Million)

TABLE 151 South Africa market size, by type, 2016 - 2027 (USD Million)

TABLE 152 South Africa market size, by age group, 2016 - 2027 (USD Million)

TABLE 153 Saudi Arabia market size, by drug class, 2016 - 2027 (USD Million)

TABLE 154 Saudi Arabia market size, by indication, 2016 - 2027 (USD Million)

TABLE 155 Saudi Arabia market size, by type, 2016 - 2027 (USD Million)

TABLE 156 Saudi Arabia market size, by age group, 2016 - 2027 (USD Million)

TABLE 157 UAE market size, by drug class, 2016 - 2027 (USD Million)

TABLE 158 UAE market size, by indication, 2016 - 2027 (USD Million)

TABLE 159 UAE market size, by type, 2016 - 2027 (USD Million)

TABLE 160 UAE market size, by age group, 2016 - 2027 (USD Million)

 

Charts & Figures

FIG. 1   Anti-viral drugs industry 360º synopsis, 2016 – 2027

FIG. 2   Industry segmentation

FIG. 3   Global anti-viral drugs industry landscape, 2016 – 2027 (USD Million)

FIG. 4   Growth potential analysis, by drug class

FIG. 5   Growth potential analysis, by indication

FIG. 6   Growth potential analysis, by type

FIG. 7   Growth potential analysis, by age group

FIG. 8   Porter’s analysis

FIG. 9   PESTEL analysis

FIG. 10 Key segment trends, by drug class

FIG. 11 Key segment trends, by indication

FIG. 12 Key segment trends, by type

FIG. 13 Key segment trends, by age group

FIG. 14 Key regional trends

FIG. 15 Competitive dashboard, 2020

 

Premium Report Details

  • Published Date: Mar 2021
  • Pages: 200
  • Tables: 160
  • Charts / Figures: 15
  • Companies covered: 10
  • Countries covered: 28

Get a report that explains COVID-19 impact on this market

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X